Reperfusion injury future or investigational therapies: Difference between revisions
Sara Mohsin (talk | contribs) No edit summary |
No edit summary |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{Reperfusion injury}} | {{Reperfusion injury}} | ||
{{CMG}} {{AE}} {{AC}}{{Shivam Singla}} | |||
==Overview== | ==Overview== | ||
A lot of studies done in the past three decades helped a lot in understanding the [[molecular]] mechanisms associated with [[Ischemia-reperfusion injury]]. Also, these studies helped in evaluating various strategies to decrease the [[incidence]] and severity associated with [[Ischemia-reperfusion injury]]. | |||
Existing therapies for [[Ischemia-reperfusion injury]] can be divided into [[Pharmacological]] and [[non-pharmacological]] interventions. A lot of promising studies and [[clinical trials]] are still under the pipeline. Till the date, the most encouraging results are associated with [[ischemic]] preconditioning and postconditioning, [[adenosine]], and [[exenatide]]. A lot of studies have demonstrated the combined effect of [[pharmacological]] and [[nonpharmacological]] approach as together to be used as a multifactorial approach to improve the [[clinical]] outcomes. | |||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
While there has been significant progress made in understanding repercussion injury, from molecular mechanisms to bedside clinical interventional, there are several areas that warrant further study. Some of these topics were outlined by the 2010 National Heart, Lung, and Blood Institute Workshop on Cardioprotection<ref name="pmid21900096">{{cite journal| author=Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E et al.| title=New horizons in cardioprotection: recommendations from the 2010 national heart, lung, and blood institute workshop. | journal=Circulation | year= 2011 | volume= 124 | issue= 10 | pages= 1172-9 | pmid=21900096 | doi=10.1161/CIRCULATIONAHA.111.032698 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21900096 }} </ref>, and include: | While there has been significant [[progress]] made in understanding [[repercussion injury]], from molecular mechanisms to bedside [[clinical]] interventional, there are several areas that warrant further study. Some of these topics were outlined by the 2010 National [[Heart]], [[Lung]], and [[Blood]] Institute Workshop on [[Cardioprotection]]<ref name="pmid21900096">{{cite journal| author=Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E et al.| title=New horizons in cardioprotection: recommendations from the 2010 national heart, lung, and blood institute workshop. | journal=Circulation | year= 2011 | volume= 124 | issue= 10 | pages= 1172-9 | pmid=21900096 | doi=10.1161/CIRCULATIONAHA.111.032698 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21900096 }} </ref>, and include: | ||
#Identifying the molecular and subcellular mechanisms responsible for postconditioning, remote conditioning, and preconditioning. | #Identifying the [[molecular]] and [[subcellular mechanisms]] responsible for [[postconditioning]], remote conditioning, and preconditioning. | ||
#Determining whether the protective mechanism triggered by remote conditioning is humoral, neural, or both. | #Determining whether the protective mechanism triggered by remote conditioning is [[humoral]], [[neural]], or both. | ||
#Investigating whether age, obesity, and diabetes mellitus may attenuate the beneficial effects of cardioprotective strategies. | #Investigating whether [[age]], [[obesity]], and [[diabetes mellitus]] may attenuate the beneficial effects of [[cardioprotective strategies]]. | ||
#Developing additional pharmacological strategies that mimic, synergize, or augment the protection exerted by conditioning protocols in conjunction with repercussion. | #Developing additional [[pharmacological strategies]] that mimic, synergize, or augment the protection exerted by conditioning protocols in conjunction with repercussion<ref name="pmid27033199">{{cite journal |vauthors=Chi HJ, Chen ML, Yang XC, Lin XM, Sun H, Zhao WS, Qi D, Dong JL, Cai J |title=Progress in Therapies for Myocardial Ischemia Reperfusion Injury |journal=Curr Drug Targets |volume=18 |issue=15 |pages=1712–1721 |date=2017 |pmid=27033199 |doi=10.2174/1389450117666160401120308 |url=}}</ref>. | ||
#Establishing a cardioprotective clinical trial network concurrent with the existing and complementary preclinical network (CAESAR) to test promising cardioprotective agents and strategies in patients in the setting of both acute myocardial infarction and cardiac surgery. | #Establishing a [[cardioprotective]] [[clinical trial]] network concurrent with the existing and complementary preclinical network (CAESAR) to test promising [[cardioprotective agents]] and strategies in [[patients]] in the setting of both [[acute myocardial infarction]] and [[cardiac]] [[surgery]]. | ||
==References== | ==References== | ||
| Line 25: | Line 23: | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Up-To-Date cardiology]] | [[Category: Up-To-Date cardiology]] | ||
Latest revision as of 00:57, 23 August 2020
|
Reperfusion injury Microchapters |
|
Treatment |
|---|
|
Reperfusion injury future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Reperfusion injury future or investigational therapies |
|
FDA on Reperfusion injury future or investigational therapies |
|
CDC on Reperfusion injury future or investigational therapies |
|
Reperfusion injury future or investigational therapies in the news |
|
Blogs on Reperfusion injury future or investigational therapies |
|
Risk calculators and risk factors for Reperfusion injury future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anjan K. Chakrabarti, M.D. [2]Shivam Singla, M.D.[3]
Overview
A lot of studies done in the past three decades helped a lot in understanding the molecular mechanisms associated with Ischemia-reperfusion injury. Also, these studies helped in evaluating various strategies to decrease the incidence and severity associated with Ischemia-reperfusion injury. Existing therapies for Ischemia-reperfusion injury can be divided into Pharmacological and non-pharmacological interventions. A lot of promising studies and clinical trials are still under the pipeline. Till the date, the most encouraging results are associated with ischemic preconditioning and postconditioning, adenosine, and exenatide. A lot of studies have demonstrated the combined effect of pharmacological and nonpharmacological approach as together to be used as a multifactorial approach to improve the clinical outcomes.
Future or Investigational Therapies
While there has been significant progress made in understanding repercussion injury, from molecular mechanisms to bedside clinical interventional, there are several areas that warrant further study. Some of these topics were outlined by the 2010 National Heart, Lung, and Blood Institute Workshop on Cardioprotection[1], and include:
- Identifying the molecular and subcellular mechanisms responsible for postconditioning, remote conditioning, and preconditioning.
- Determining whether the protective mechanism triggered by remote conditioning is humoral, neural, or both.
- Investigating whether age, obesity, and diabetes mellitus may attenuate the beneficial effects of cardioprotective strategies.
- Developing additional pharmacological strategies that mimic, synergize, or augment the protection exerted by conditioning protocols in conjunction with repercussion[2].
- Establishing a cardioprotective clinical trial network concurrent with the existing and complementary preclinical network (CAESAR) to test promising cardioprotective agents and strategies in patients in the setting of both acute myocardial infarction and cardiac surgery.
References
- ↑ Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E; et al. (2011). "New horizons in cardioprotection: recommendations from the 2010 national heart, lung, and blood institute workshop". Circulation. 124 (10): 1172–9. doi:10.1161/CIRCULATIONAHA.111.032698. PMID 21900096.
- ↑ Chi HJ, Chen ML, Yang XC, Lin XM, Sun H, Zhao WS, Qi D, Dong JL, Cai J (2017). "Progress in Therapies for Myocardial Ischemia Reperfusion Injury". Curr Drug Targets. 18 (15): 1712–1721. doi:10.2174/1389450117666160401120308. PMID 27033199.